Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer
CTGF is a key mediator of resistance to AATs in ccRCC, by promoting tumor progression and remodeling the tumor microenvironment. CTGF may thus serve as both a predictive biomarker and a therapeutic target. These findings support further investigation of CTGF inhibition as a strategy to overcome AAT resistance and improve treatment outcomes in ccRCC patients.
Authors
- Jérôme Durivault (ORCID: https://orcid.org/0000-0002-8228-2915)
- Emmanuel Chamorey (ORCID: https://orcid.org/0000-0002-6841-4571)
- Maeva Dufies
- Sandy Giuliano (ORCID: https://orcid.org/0000-0001-7580-0326)
- Julien Parola
- Manon Teisseire (ORCID: https://orcid.org/0000-0002-0035-0532)
- Yihai Cao
- Damien Ambrosetti
- Gilles Pagès
- Renaud Schiappa
- Arthur Karaulic
- Frédéric Luciano
- Delphine Borchiellini
- Tanguy Pace-Loscos
- Maëva Totobesola
- Juan Gao
Institutions
- Centre National de la Recherche Scientifique (FR)
- International University of Monaco (MC)
- Inserm (FR)
- Karolinska Institutet (SE)
- Centre Hospitalier Universitaire de Nice (FR)
- Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR)
- Scientific Centre of Monaco (MC)
- Centre Antoine Lacassagne (FR)
Publication Details
- Journal
- Theranostics
- Published
- 2026-02-11
- DOI
- https://doi.org/10.7150/thno.125269
- Primary Topic
- Connective Tissue Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Infrastructures en Biologie Santé et Agronomie
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Karolinska Institutet
- Fondation ARC pour la Recherche sur le Cancer
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Canceropôle PACA
- Institut National Du Cancer
- Conseil Régional Provence-Alpes-Côte d'Azur
- Horizon 2020 Framework Programme